

## Staphylococcus aureus - VRS1

### Other designations ( HIP11714 )

Demographic Information:			
Country/State:	United States / Michigan	Date of Isolation:	06/01/2002
Patient Age:	40 Year(s)	Gender:	N/A
Patient Location:	Outpatient	Patient Service:	Renal Dialysis
Culture Source:	Catheter exit site		
Literature Citation:	CDC. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002 July;51(26):565-567.		
Donor Reported MIC Results (ug/ml)	Vancomycin > 128	Teicoplanin = 32	
Comment:	For stability purposes, it is recommended that the strain is subcultured in the presence of vancomycin.		
Repositories:	Glycopeptide Resistant Staphylococci		

#### NARSA Antimicrobial Susceptibility Data for Glycopeptides

Drug	Broth Microdilution		<sup>a</sup> Conventional Etest 0.5 McFarland Std		<sup>b</sup> Modified Etest 2 McFarland Std		<sup>c</sup> BHI Agar Screen	Disk Diffusion	
	<del>MIC</del> MIC <del>(ug/ml)</del> µg/mL	CLSI Interprtn	MIC µg/ml	CLSI Interprtn	MIC µg/ml	CLSI Interprtn		Zone diam. (mm)	CLSI Interprtn
<b>Vancomycin:</b>	> 256	R	> 256	R	> 256	R	CG(24)	6	NS
<b>Teicoplanin:</b>	= 64	R	> 256	R	> 256	R		6	R

S = Susceptible; R = Resistant; NS = Not Susceptible; I = Intermediate; N/A = Not Available P = Pending results

NARSA Antimicrobial Profile for Other Antimicrobial Agents			Molecular Characterization Data	
Drug	<del>MIC</del> MIC <del>(ug/ml)</del> µg/mL	CLSI Interprtn	PCR	Result
<b>Ciprofloxacin</b>	> 16	R	<b>vanA</b>	POSITIVE
<b>Clindamycin</b>	> 4	R	<b>vanB</b>	NEGATIVE
<b>Erythromycin</b>	> 8	R	<b>vanC1</b>	NEGATIVE
<b>Gentamicin</b>	> 16	R	<b>vanC2</b>	NEGATIVE
<b>Linezolid</b>	= 2	S	<b>vanD</b>	NEGATIVE
<b>Oxacillin</b>	> 16	R	<b>vanE</b>	NEGATIVE
<b>Penicillin</b>	> 2	R	<b>mecA</b>	POSITIVE
<b>Quinupristin/dalfopristin</b>	= 0.5	S		
<b>Trimeth/sulfa</b>	= 2/38	S		